drugset / Trial / NCT04232644

Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR)

NCT04232644

Phase 1 Completed 16 enrolled Vallon Pharmaceuticals, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a pilot randomized, double-blind, active-controlled, 2-treatment, crossover study to evaluate the PK, user experience and abuse liability of manipulated ADAIR compared to a manipulated commercially-available d-amphetamine sulfate IR formulation administered intranasally in non-dependent recreational stimulant users. The study is comprised of 4 phases: Screening, Qualification, Treatment, and Follow-up/Early Termination.

Timeline

Start
2019-05-27
Primary completion
2019-07-17
Completion
2019-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject ADAIR Unknown 30 mg Intranasal
Subject Dextroamphetamine Small molecule 30 mg Intranasal